Cidofovir: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
* Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97 |
* Unlike [[ganciclovir]], it does ''not'' need phosphorylation by UL97 |
||
* Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}} |
* Indications: {{#ask: [[Is treated by::cidofovir]] | default=none}} |
||
| − | * Major adverse effect is irreversible renal tubular necrosis, which may be prevented by probenecid |
+ | * Major adverse effect is [[Adverse drug reaction::irreversible renal tubular necrosis]], which may be prevented by probenecid |
[[Category:Antivirals]] |
[[Category:Antivirals]] |
||
Revision as of 23:19, 17 February 2020
- Cytosine nucleotide analogue that inhibits DNA polymerase in human herpesviruses
- Should be given with probenecid 2 g IV prior to each dose
- Unlike ganciclovir, it does not need phosphorylation by UL97
- Indications: Adenovirus, CMV after solid organ transplantation, Cytomegalovirus, Herpes simplex virus
- Major adverse effect is irreversible renal tubular necrosis, which may be prevented by probenecid
